Literature DB >> 9365760

Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection.

W B Dyer1, A F Geczy, S J Kent, L B McIntyre, S A Blasdall, J C Learmont, J S Sullivan.   

Abstract

OBJECTIVES: To assess T-helper cell immune function (proliferation) in members of the Sydney Blood Bank Cohort (SBBC) compared with other individuals with transfusion- and sexually acquired HIV-1 infection and with matched HIV-negative controls. DESIGN AND METHODS: Decreasing CD4 counts and T-helper cell function are associated with disease progression. Peripheral blood mononuclear cells (PBMC) from study subjects were assayed for in vitro proliferative responses to HIV-1-derived antigens, recall antigens and alloantigen. T-helper cell function and CD4 counts in members of the SBBC were followed longitudinally.
RESULTS: Proliferative responses and CD4 counts from members of the SBBC were similar to or better than those of other transfusion- or sexually-acquired HIV-1-positive long-term non-progressors (LTNP), including the HIV-negative matched SBBC control groups. However, individuals with disease progression had reduced or undetectable proliferative responses to recall antigens but a conserved response to alloantigen; they also had low CD4 counts and low CD4:CD8 ratios. In the SBBC, these immune parameters were usually stable over time.
CONCLUSIONS: The unique SBBC with natural nef/long terminal repeat deletions in the HIV-1 genome were genuine LTNP without showing signs of disease progression. They appeared to be a group distinct from the tail-end of the normal distribution of disease progression rates, and may remain asymptomatic indefinitely. The SBBC virus may form the basis of a live attenuated immunotherapeutic or immunoprophylactic HIV vaccine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365760     DOI: 10.1097/00002030-199713000-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  28 in total

1.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Simultaneous assessment of CD4 and MHC-I downregulation by Nef primary isolates in the context of infection.

Authors:  Ayub Ali; Susan Realegeno; Otto O Yang; Martha J Lewis
Journal:  J Virol Methods       Date:  2009-07-28       Impact factor: 2.014

3.  HIV-1 Nef disrupts intracellular trafficking of major histocompatibility complex class I, CD4, CD8, and CD28 by distinct pathways that share common elements.

Authors:  Jolie A Leonard; Tracy Filzen; Christoph C Carter; Malinda Schaefer; Kathleen L Collins
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production.

Authors:  M C Gauduin; R L Glickman; S Ahmad; T Yilma; R P Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 5.  HIV immune evasion disruption of antigen presentation by the HIV Nef protein.

Authors:  Elizabeth R Wonderlich; Jolie A Leonard; Kathleen L Collins
Journal:  Adv Virus Res       Date:  2011       Impact factor: 9.937

6.  Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles.

Authors:  Michael Schindler; Stephanie Würfl; Philippe Benaroch; Thomas C Greenough; Rod Daniels; Philippa Easterbrook; Matthias Brenner; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1.

Authors:  W B Dyer; G S Ogg; M A Demoitie; X Jin; A F Geczy; S L Rowland-Jones; A J McMichael; D F Nixon; J S Sullivan
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 8.  Immune dysregulation in human immunodeficiency virus infection: know it, fix it, prevent it?

Authors:  A Boasso; G M Shearer; C Chougnet
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

9.  Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo.

Authors:  W David Wick; Peter B Gilbert; Otto O Yang
Journal:  J Virol       Date:  2008-12-17       Impact factor: 5.103

10.  Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity.

Authors:  Lori A Emert-Sedlak; Purushottam Narute; Sherry T Shu; Jerrod A Poe; Haibin Shi; Naveena Yanamala; John Jeff Alvarado; John S Lazo; Joanne I Yeh; Paul A Johnston; Thomas E Smithgall
Journal:  Chem Biol       Date:  2013-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.